



1,920 Results

Any time ▾

## Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in ...

[nature.com](#) › [british journal of cancer](#)

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study ... the gastroesophageal junction: safety ...

Author: Simon Pernot, Olivier Dubreuil, Thoma... Publish Year: 2018

## Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in ...

[https://www.researchgate.net/publication/325605279\\_Efficacy\\_of\\_a...](https://www.researchgate.net/publication/325605279_Efficacy_of_a...)

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study Article in British Journal of Cancer 119 ...

## Adjuvant and/or neoadjuvant therapy for gastric cancer? A ...

[www.ncbi.nlm.nih.gov](#) › ... › Ther Adv Med Oncol › v.7(1); 2015 Jan

Both trials directly compared surgery with or without neoadjuvant or perioperative CT and showed a significant benefit for the multimodal approach. ... which demonstrated the beneficial effects of trastuzumab for HER2-positive advanced gastric and gastroesophageal junction cancers in ...

Agboola O. (1994) Adjuvant treatment in gastric cancer ...

Cited by: 15

Author: Rebekka Schirren, Daniel Reim, Alexande...

Publish Year: 2015

## Efficacy and safety of trastuzumab in combination with ...

<https://www.sciencedirect.com/science/article/pii/S000745511500048X>

Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based ... Based on the randomized phase III Trastuzumab for Gastric Cancer (ToGA) study ... al.Trastuzumab (TRA) in combination with different first-line chemotherapies for treatment of HER2-positive metastatic gastric or gastroesophageal junction cancer ...

**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 47547

**Manuscript Type:** ORIGINAL ARTICLE

*Retrospective Study*

**Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study**

Valeria Basso, David Orry, Jean Fraisse, Julie Vincent, Audrey Hennequin, Leila Bengrine, Francois Ghiringhelli

### Match Overview

**1** **Crossref** 108 words  
Simon Pernot, Olivier Dubreuil, Thomas Aparicio, Karine Le M  
alicot et al. "Efficacy of a docetaxel-5FU-oxaliplatin regimen

4%



国内版

国际版

Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuz



All

Images

Videos

翻译成中文

开启取词

11,800 Results

Any time ▾

### Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in ...

[https://www.researchgate.net/publication/325605279\\_Efficacy\\_of\\_a\\_docetaxel-5FU...](https://www.researchgate.net/publication/325605279_Efficacy_of_a_docetaxel-5FU...)

Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: Safety and efficacy in a ...

### Efficacy and safety of trastuzumab in combination with ...

<https://www.sciencedirect.com/science/article/pii/S000745511500048X>

The aim of this retrospective observational study was to evaluate the efficacy and safety of trastuzumab in combination with LV5-FU plus oxaliplatin (mFOLFOX6) or with capecitabine plus oxaliplatin (XELOX) regimen as first-line treatment for HER2-positive AGC and AGOJ patients.

Cited by: 14

Author: Émilie Soularue, Romain Cohen, Christo...

Publish Year: 2015

### HER2-positive gastric cancer - PubMed Central (PMC)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889288>

Apr 07, 2013 · Efficacy and safety of trastuzumab in gastric cancer: the ToGA trial. The ToGA trial was a prospective, phase 3, open-label trial in which patients with HER2-positive advanced gastric or gastroesophageal junction cancer were randomly allocated to receive either trastuzumab in combination with chemotherapy or chemotherapy alone. Chemotherapy was given every 3 weeks for six cycles.

Cited by: 140

Author: Narikazu Boku

Publish Year: 2014

### Safety and efficacy of nivolumab in combination with S-1 ...

<https://academic.oup.com/annonc/article/30/2/250/5253174> ▾

Dec 19, 2018 · Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

Cited by: 1

Author: N Boku, M H Ryu, K Kato, H C Chung, K ...

Publish Year: 2019

Author: Boku, N

### Bevacizumab combined with docetaxel, oxaliplatin, and ...

[onlinelibrary.wiley.com/doi/10.1002/cncr.29864/supinfo](https://onlinelibrary.wiley.com/doi/10.1002/cncr.29864/supinfo)

Gastric cancer (GC) has a poor prognosis, with a cancer-related mortality rate of 75%. 1 For patients with advanced disease, palliative chemotherapy is the main treatment option. 2 The majority of regimens are based on fluoropyrimidines and platinum, and 5-fluorouracil (5-FU)-based combination chemotherapy has been shown to provide superior overall survival (OS) and quality of life compared with single-agent 5-FU...

Cited by: 16

Author: Didier Meulendijks, Jan Willem B. de Gro...

Publish Year: 2016

### Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin ...

<https://link.springer.com/article/10.1007/s10120-013-0266-6> ▾

Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in